Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview
出版年份 2016 全文链接
标题
Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview
作者
关键词
-
出版物
MEDICINAL RESEARCH REVIEWS
Volume 37, Issue 2, Pages 314-367
出版商
Wiley
发表日期
2016-10-24
DOI
10.1002/med.21409
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Anilinoquinazoline inhibitors of the RET kinase domain—Elaboration of the 7-position
- (2016) Allan M. Jordan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Recent progress on third generation covalent EGFR inhibitors
- (2016) Hengmiao Cheng et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeting the fibroblast growth factor receptor family in cancer
- (2016) Niamh Hallinan et al. CANCER TREATMENT REVIEWS
- Osimertinib: First Global Approval
- (2016) Sarah L. Greig DRUGS
- Efficacy of lenvatinib in treating thyroid cancer
- (2016) Jolanta Krajewska et al. EXPERT OPINION ON PHARMACOTHERAPY
- Unveiling new chemical scaffolds as Mnk inhibitors
- (2016) Sarah Diab et al. Future Medicinal Chemistry
- Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
- (2016) Michael Crump et al. JOURNAL OF CLINICAL ONCOLOGY
- Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase
- (2016) Craig Fraser et al. JOURNAL OF MEDICINAL CHEMISTRY
- Lessons from breast cancer trials of HER2-kinase inhibitors
- (2016) Ian E Krop LANCET ONCOLOGY
- Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
- (2016) E. Ardini et al. MOLECULAR CANCER THERAPEUTICS
- Targeting CK2-driven non-oncogene addiction in B-cell tumors
- (2016) E Mandato et al. ONCOGENE
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Choline kinase alpha—Putting the ChoK-hold on tumor metabolism
- (2016) Sean P. Arlauckas et al. PROGRESS IN LIPID RESEARCH
- Illuminating the Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance for the FGFR1 Gatekeeper Mutation: The Achilles’ Heel of Targeted Therapy
- (2015) Christal D. Sohl et al. ACS Chemical Biology
- Recent progress on MAP kinase pathway inhibitors
- (2015) David E. Uehling et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Mechanisms of lapatinib resistance in HER2-driven breast cancer
- (2015) Valentina D’Amato et al. CANCER TREATMENT REVIEWS
- Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas
- (2015) L Alinari et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Therapeutic management of ALK+nonsmall cell lung cancer patients
- (2015) Boris Duchemann et al. EUROPEAN RESPIRATORY JOURNAL
- Targeting Pim kinases for cancer treatment: opportunities and challenges
- (2015) Bich Thuy Le et al. Future Medicinal Chemistry
- Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives
- (2015) Joan Minguet et al. INTERNATIONAL JOURNAL OF CANCER
- Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ
- (2015) John R. Somoza et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Exploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancer
- (2015) Amarnath Challapalli et al. JOURNAL OF CLINICAL PATHOLOGY
- Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer
- (2015) Minsoo Song JOURNAL OF MEDICINAL CHEMISTRY
- AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
- (2015) Samuel H. Myers et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
- (2015) Isabella Zhang et al. LANCET ONCOLOGY
- Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
- (2015) Chee-Seng Tan et al. LANCET ONCOLOGY
- Prolonged and tunable residence time using reversible covalent kinase inhibitors
- (2015) J Michael Bradshaw et al. Nature Chemical Biology
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- The drug–target residence time model: a 10-year retrospective
- (2015) Robert A. Copeland NATURE REVIEWS DRUG DISCOVERY
- Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy
- (2015) R Mandal et al. ONCOGENE
- Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials
- (2015) M. Burotto et al. ONCOLOGIST
- FAK signaling in human cancer as a target for therapeutics
- (2015) Brian Y. Lee et al. PHARMACOLOGY & THERAPEUTICS
- Targeting the Pim kinases in multiple myeloma
- (2015) N A Keane et al. Blood Cancer Journal
- First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
- (2015) M. Hagel et al. Cancer Discovery
- Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
- (2015) Diletta Fontana et al. Cancer Medicine
- Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer
- (2015) Jolanta Krajewska et al. Expert Review of Clinical Pharmacology
- Nintedanib in the treatment of idiopathic pulmonary fibrosis
- (2015) Mariano E. Mazzei et al. Therapeutic Advances in Respiratory Disease
- Aurora Kinase Inhibitors: Current Status and Outlook
- (2015) Vassilios Bavetsias et al. Frontiers in Oncology
- Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
- (2015) Julie A. Zorn et al. PLoS One
- Targeting Mnks for Cancer Therapy
- (2015) Jinqiang Hou et al. Oncotarget
- Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels
- (2015) Jörg Haupenthal et al. NEOPLASIA
- Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
- (2014) Zheng Zhao et al. ACS Chemical Biology
- The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor
- (2014) Yong-Soon Cho et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- p38 MAPK in cardioprotection - are we there yet?
- (2014) E D Martin et al. BRITISH JOURNAL OF PHARMACOLOGY
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- Fostamatinib disodium
- (2014) F.W.K. Tam et al. DRUGS OF THE FUTURE
- B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells
- (2014) Vaclav Seda et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors
- (2014) Toshirou Nishida et al. EXPERT OPINION ON PHARMACOTHERAPY
- Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?
- (2014) Matthew C Lucas et al. Future Medicinal Chemistry
- Pim kinases in hematological malignancies: where are we now and where are we going?
- (2014) Patrizia Mondello et al. Journal of Hematology & Oncology
- Understanding the Roles of FAK in Cancer
- (2014) Hyunho Yoon et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
- (2014) M. Raymond V. Finlay et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
- (2014) Ted W. Johnson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients
- (2014) Carlo Gambacorti Passerini et al. JNCI-Journal of the National Cancer Institute
- The role of ligand efficiency metrics in drug discovery
- (2014) Andrew L. Hopkins et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crenolanib is a selective type I pan-FLT3 inhibitor
- (2014) C. C. Smith et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
- (2014) Li Tan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Getting Syk: spleen tyrosine kinase as a therapeutic target
- (2014) Robert L. Geahlen TRENDS IN PHARMACOLOGICAL SCIENCES
- TRKing Down an Old Oncogene in a New Era of Targeted Therapy
- (2014) Aria Vaishnavi et al. Cancer Discovery
- Sulfoximines: A Neglected Opportunity in Medicinal Chemistry
- (2013) Ulrich Lücking ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation
- (2013) Pascal Furet et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
- (2013) J. Mascarenhas et al. BLOOD
- PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
- (2013) Carolyn D. Britten CANCER CHEMOTHERAPY AND PHARMACOLOGY
- SnapShot: p38 MAPK Signaling
- (2013) Natalia Trempolec et al. CELL
- Targeting the PDGF signaling pathway in tumor treatment
- (2013) Carl-Henrik Heldin Cell Communication and Signaling
- Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis
- (2013) A. Kalota et al. CLINICAL CANCER RESEARCH
- Cdks, cyclins and CKIs: roles beyond cell cycle regulation
- (2013) S. Lim et al. DEVELOPMENT
- T315I, more or less, predicts for major molecular response: the devil is in the details!
- (2013) M. J. Mauro HAEMATOLOGICA
- Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases
- (2013) Matt Addie et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib
- (2013) Oliver Gautschi et al. Journal of Thoracic Oncology
- Which drug, and when, for patients with BRAF-mutant melanoma?
- (2013) Sekwon Jang et al. LANCET ONCOLOGY
- mTOR kinase structure, mechanism and regulation
- (2013) Haijuan Yang et al. NATURE
- Irreversible kinase inhibitors gain traction
- (2013) Katharine Sanderson NATURE REVIEWS DRUG DISCOVERY
- Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
- (2013) Tara R. Rheault et al. ACS Medicinal Chemistry Letters
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- Targeted Small-Molecule Inhibitors of Protein Kinase B as Anticancer Agents
- (2012) Ian Collins Anti-Cancer Agents in Medicinal Chemistry
- Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy
- (2012) Hagop Kantarjian et al. CANCER
- TGF-β signalling and its role in cancer progression and metastasis
- (2012) Yvette Drabsch et al. CANCER AND METASTASIS REVIEWS
- Fragment Based Drug Design: From Experimental to Computational Approaches
- (2012) A. Kumar et al. CURRENT MEDICINAL CHEMISTRY
- Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy
- (2012) Nicola Rath et al. EMBO REPORTS
- Discovery and characterization of novel allosteric FAK inhibitors
- (2012) Misa Iwatani et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAFV600Emutation
- (2012) Kate Young et al. Future Oncology
- The p110 and p110 isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis
- (2012) T. Utermark et al. GENES & DEVELOPMENT
- Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?
- (2012) Andrea Gombos et al. INVESTIGATIONAL NEW DRUGS
- LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
- (2012) S. Betty Yan et al. INVESTIGATIONAL NEW DRUGS
- Aurora kinase inhibitors: Progress towards the clinic
- (2012) Madhu Kollareddy et al. INVESTIGATIONAL NEW DRUGS
- Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
- (2012) Naifa L. Busaidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors
- (2012) Mark A. Ashwell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cutaneous toxicities of RAF inhibitors
- (2012) Rachael Anforth et al. LANCET ONCOLOGY
- ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
- (2012) G. Hatzivassiliou et al. MOLECULAR CANCER THERAPEUTICS
- Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
- (2012) H.-J. Nam et al. MOLECULAR CANCER THERAPEUTICS
- MET: a promising anticancer therapeutic target
- (2012) Solange Peters et al. Nature Reviews Clinical Oncology
- Targeting the TGFβ signalling pathway in disease
- (2012) Rosemary J. Akhurst et al. NATURE REVIEWS DRUG DISCOVERY
- MAP kinase signaling and inhibition in melanoma
- (2012) R J Sullivan et al. ONCOGENE
- Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications
- (2012) Johan Lennartsson et al. PHYSIOLOGICAL REVIEWS
- VEGF Inhibition, Hypertension, and Renal Toxicity
- (2012) Suzanne R. Hayman et al. Current Oncology Reports
- PLK1 as an oncology target: current status and future potential
- (2011) Campbell McInnes et al. DRUG DISCOVERY TODAY
- Structural Basis for Selective Small Molecule Kinase Inhibition of Activated c-Met
- (2011) Keith W. Rickert et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197
- (2011) Sudharshan Eathiraj et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein
- (2011) Kathleen Aertgeerts et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold
- (2011) Tomoyasu Ishikawa et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer
- (2011) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
- (2011) Alfonso Quintás-Cardama et al. NATURE REVIEWS DRUG DISCOVERY
- The resurgence of covalent drugs
- (2011) Juswinder Singh et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
- (2011) Siyuan Zhang et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- PI3K/p110 is a novel therapeutic target in multiple myeloma
- (2010) H. Ikeda et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Unveiling the Secrets of the Ancestral PI3 Kinase Vps34
- (2010) Paul Workman et al. CANCER CELL
- Reduced SMAD7 Leads to Overactivation of TGF- Signaling in MDS that Can Be Reversed by a Specific Inhibitor of TGF- Receptor I Kinase
- (2010) L. Zhou et al. CANCER RESEARCH
- Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
- (2010) P. Workman et al. CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
- (2010) Y. Dai et al. CLINICAL CANCER RESEARCH
- Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy
- (2010) A. Montagnoli et al. CLINICAL CANCER RESEARCH
- Non-ATP Competitive Protein Kinase Inhibitors
- (2010) L. Garuti et al. CURRENT MEDICINAL CHEMISTRY
- Crystal Structures of Human Choline Kinase Isoforms in Complex with Hemicholinium-3
- (2010) Bum Soo Hong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)
- (2010) Tatiana McHardy et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer
- (2010) Fabrice Pierre et al. JOURNAL OF MEDICINAL CHEMISTRY
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
- (2010) Alex Berndt et al. Nature Chemical Biology
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
- (2010) Wen-I Wu et al. PLoS One
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crystal Structures of MEK1 Binary and Ternary Complexes with Nucleotides and Inhibitors
- (2009) Thierry O. Fischmann et al. BIOCHEMISTRY
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
- (2009) C. Iverson et al. CANCER RESEARCH
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- On Trk--The TrkB Signal Transduction Pathway Is an Increasingly Important Target in Cancer Biology
- (2009) C. J. Thiele et al. CLINICAL CANCER RESEARCH
- Protein kinase C intervention—the state of play
- (2009) Jon Roffey et al. CURRENT OPINION IN CELL BIOLOGY
- Cdc7 kinase – A new target for drug development
- (2009) Ronan Swords et al. EUROPEAN JOURNAL OF CANCER
- Novel Synthesis and Structural Characterization of a High-Affinity Paramagnetic Kinase Probe for the Identification of Non-ATP Site Binders by Nuclear Magnetic Resonance
- (2009) Franklin J. Moy et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory Disorders
- (2009) David M. Goldstein et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selectively Nonselective Kinase Inhibition: Striking the Right Balance
- (2009) Richard Morphy JOURNAL OF MEDICINAL CHEMISTRY
- Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
- (2008) Peter J. Tummino et al. BIOCHEMISTRY
- Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling
- (2008) M. S. Raab et al. BLOOD
- Therapeutic Protein Kinase Inhibitors
- (2008) S. K. Grant CELLULAR AND MOLECULAR LIFE SCIENCES
- Small-Molecule Inhibitors of PDK1
- (2008) Christian Peifer et al. ChemMedChem
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia
- (2008) M.-C. Crouthamel et al. CLINICAL CANCER RESEARCH
- Epidermal Growth Factor Receptor Inhibitor–Related Skin Toxicity: Mechanisms, Treatment, and its Potential Role as a Predictive Marker
- (2008) Diletta Bianchini et al. Clinical Colorectal Cancer
- Target specificity and off-target effects as determinants of cancer drug efficacy
- (2008) Maria C Shoshan et al. Expert Opinion on Drug Metabolism & Toxicology
- Identification of 4-(4-Aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as Selective Inhibitors of Protein Kinase B through Fragment Elaboration
- (2008) John J. Caldwell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dermatologic symptoms associated with the multikinase inhibitor sorafenib
- (2008) Caroline Robert et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KITD816V
- (2008) Celalettin Ustun et al. LEUKEMIA RESEARCH
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- High-throughput kinase profiling as a platform for drug discovery
- (2008) David M. Goldstein et al. NATURE REVIEWS DRUG DISCOVERY
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
- Do molecularly targeted agents in oncology have reduced attrition rates?
- (2008) Ian Walker et al. NATURE REVIEWS DRUG DISCOVERY
- The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer
- (2008) P. D. Ryan et al. ONCOLOGIST
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
- (2008) S WANG et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Novel paradigms for drug discovery: computational multitarget screening
- (2008) E JENWITHEESUK et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Development trends for new cancer therapeutics and vaccines
- (2007) J REICHERT DRUG DISCOVERY TODAY
- Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice
- (2007) Cordelia J. Barrick et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started